Mayne Pharma has entered into an exclusive license and supply agreement with Mithra Pharmaceuticals SA to commercialize E4/DRSP, a combined oral contraceptive, in the U.S. The product is expected to be launched in first half of calendar 2021, subject to U.S. FDA approval. On approval the product is expected to receive five-year New Chemical Entity (NCE) exclusivity from the FDA, with potential for patent protection beyond 2030.   E4/DRSP is a novel, next generation combined oral contraceptive co...